Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Device recalls, FDA approvals, and multi-segment revenue shifts make Boston Scientific’s disclosures some of the densest in the medical-technology arena. Sifting through hundreds of pages to locate litigation updates or pipeline milestones can slow critical decisions. Stock Titan eliminates that bottleneck with AI-powered summaries that turn complex language into clear takeaways—Boston Scientific SEC filings explained simply.
Need the numbers behind the latest Boston Scientific quarterly earnings report 10-Q filing or a Boston Scientific annual report 10-K simplified? Our platform links each line item to cardiovascular and MedSurg product families, highlights new reimbursement risks, and flags R&D outlays tied to next-gen ablation catheters. Real-time alerts cover every Boston Scientific 8-K material events explained notice, while side-by-side charts deliver Boston Scientific earnings report filing analysis without exporting spreadsheets. Insider activity matters too: follow Boston Scientific insider trading Form 4 transactions and receive push notifications on Boston Scientific Form 4 insider transactions real-time—ideal for spotting executive sentiment ahead of approvals.
From tracking Boston Scientific executive stock transactions Form 4 to decoding a Boston Scientific proxy statement executive compensation table, our AI focuses on the issues that drive valuation: recall reserves, clinical-trial spend, and regional sales trends. Whether you’re a portfolio manager, sell-side analyst, or healthcare consultant, understanding Boston Scientific SEC documents with AI means less time searching and more time acting on insights.
Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported multiple transactions on 09/02/2025 effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2025. The report shows 50,000 shares acquired at a price of $26.15 (code M) and two dispositions totaling 50,000 shares sold in multiple trades at weighted average prices of $104.886 and $105.8486. After these transactions, the reporting person beneficially owned 178,342 shares directly, with an additional 5,234 shares held indirectly by his child which he disclaims beneficial ownership of. The filing includes an option related entry reflecting a 50,000-share option with the same $26.15 figure and references vesting in four equal annual installments beginning December 1, 2018.
The form is signed by an attorney-in-fact on behalf of the reporting person and discloses the reporting person will provide detailed per-price sale breakdowns upon request by the SEC or others.
Boston Scientific Corp. Form 144 notice reports a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $5,271,415.00, with an approximate sale date of 09/02/2025. The filing states these 50,000 shares were acquired the same day by stock option exercise and paid for in cash.
The filing also discloses prior sales by the same person, JOSEPH M FITZGERALD, totaling 156,372 shares across three transactions on 06/04/2025, 07/01/2025, and 08/01/2025, generating gross proceeds of $16,985,599.64 combined. The notice includes the seller's representation that no undisclosed material adverse information is known.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
